Tresiba (insulin degludec) and Levemir (insulin detemir) are both long-acting basal insulins providing steady background blood sugar control, but Tresiba lasts longer and offers more dosing-time flexibility, while Levemir often requires twice-daily dosing for full 24-hour coverage. This guide compares their duration, flexibility, and dosing.
This is general information, not medical advice.
Tresiba vs Levemir at a glance
| Tresiba (insulin degludec) | Levemir (insulin detemir) | |
|---|---|---|
| Duration of action | Up to 42 hours | Up to 24 hours |
| Typical dosing | Once daily | Once or twice daily |
| Dosing time flexibility | High (label supports flexible timing) | Lower, more consistent timing generally advised |
| Insulin type | Long-acting basal analog | Long-acting basal analog |
Both are long-acting “basal” insulins
Basal insulins provide a steady, background level of insulin throughout the day and night, separate from mealtime (bolus) insulins like Humalog or Novolog that cover food intake. Both Tresiba and Levemir fill this basal role, but with different duration profiles that affect how they’re dosed.
The duration difference
Levemir’s label describes it as a soluble, long-acting basal human insulin analog with up to a 24-hour duration of action. Because 24 hours is right at the edge of a true once-daily interval, many patients on Levemir end up needing twice-daily dosing to maintain consistent coverage without gaps, particularly if their individual response falls on the shorter end of that duration range.
Tresiba (insulin degludec) has an ultra-long duration of action, described as lasting up to 42 hours, substantially longer than Levemir. This extended duration gives Tresiba a meaningful cushion, once-daily dosing reliably covers a full 24-hour period with room to spare, which also translates into more forgiving dosing-time flexibility if a dose is taken a few hours earlier or later than usual on a given day.
Why dosing flexibility matters practically
Tresiba’s labeling specifically supports more flexibility in dosing time compared with many other basal insulins, useful for patients with variable daily schedules (shift workers, frequent travelers, or anyone who has trouble taking a dose at the exact same time every day). Levemir’s shorter duration generally calls for more consistent timing to avoid gaps in coverage, particularly for patients using it once daily rather than twice.
Starting dose considerations
Levemir’s label provides specific starting-dose guidance for insulin-naive patients with type 1 diabetes: approximately one-third to one-half of the total daily insulin dose, with the remainder given as short-acting mealtime insulin, and a general starting calculation of 0.2 to 0.4 units per kilogram of body weight for total daily insulin dose in insulin-naive type 1 patients. Tresiba dosing is similarly individualized based on total insulin needs, blood sugar patterns, and response, adjusted by the prescriber over time.
Side effects
Both share the general risks of any basal insulin: hypoglycemia if the dose exceeds actual insulin need, injection site reactions, and weight gain that can occur with insulin therapy generally. Neither has a distinctly different side-effect profile from the other beyond the practical dosing and duration differences already discussed; both are insulin analogs with well-established safety records in long-term use.
Who each might suit
Factors that may point toward Tresiba:
- A variable daily schedule where flexible dosing timing is valuable
- A need for more reliable single daily dosing without the risk of coverage gaps that can occur with Levemir’s shorter duration
- Established good glucose control history with degludec specifically
Factors that may point toward Levemir:
- A consistent daily routine where fixed-timing dosing isn’t a practical burden
- Established good control already on detemir, with no reason to switch
- Prescriber or insurance formulary preference for detemir
Frequently asked questions
Which lasts longer, Tresiba or Levemir?
Tresiba, with a duration of action up to 42 hours, compared with Levemir’s up to 24 hours.
Why would someone need to take Levemir twice a day?
Because its duration (up to 24 hours) is right at the edge of a full day, individual response variation means many patients need twice-daily dosing to maintain steady coverage without gaps.
Is Tresiba more flexible with dosing time?
Yes, its labeling specifically supports more flexibility in when the daily dose is taken, an advantage of its much longer overall duration of action compared with Levemir.
Can either be used for type 1 diabetes?
Yes, both are used as basal insulin in type 1 diabetes treatment plans, combined with mealtime insulin for full coverage.
Do these insulins need to be paired with a mealtime insulin?
Yes, as basal insulins, both are typically combined with a rapid-acting mealtime insulin (such as Humalog, Novolog, or Fiasp) for complete blood sugar management across meals and between-meal periods.